MichaelVChioreanMD
Gastroenterology • Issaquah, WAAdvanced Endoscopic Interventional, Inflammatory Bowel Disease
Physician
Dr. Chiorean is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
751 NE Blakely Dr #3020
Ste 3020
Issaquah, WA 98029Phone+1 206-215-4250- Is this information wrong?
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gastroenterology, 2000 - 2003- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1998 - 2000
Beaumont Health (Royal Oak)Internship, Internal Medicine, 1997 - 1998
Iuliu Hatieganu University of Medicine and PharmacyClass of 1992
Certifications & Licensure
WA State Medical License 2012 - 2025
TX State Medical License 2023 - 2023
IN State Medical License 2004 - 2013
OH State Medical License 2004 - 2007
MN State Medical License 1999 - 2005
MI State Medical License 1997 - 1998- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification HealthSentry EHR, Cerner Corporation, 2013
- Fellow (AGAF) American Gastroenterological Association, 2011
Clinical Trials
- Chromoendoscopy for Ulcerative Colitis Surveillance Start of enrollment: 2005 Dec 01
- Can CT Enteroclysis Predict the Outcome of Crohn's Disease Start of enrollment: 2007 Aug 01
- Prevalence of Lymphoma in IBD Start of enrollment: 2006 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States.Jeanne Jiang, Ninfa Candela, Grace Chen, Hela Romdhani, Dominick Latremouille-Viau, Sherry Shi, Rebecca Bungay, Annie Guerin, Tao Fan, Michael Chiorean> ;Current Medical Research and Opinion. 2024 Apr 8
- 2 citationsEfficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label ...Silvio Danese, Remo Panaccione, Maria T Abreu, David T Rubin, Subrata Ghosh, Axel Dignass, Anita Afzali, Douglas C Wolf, Michael V Chiorean, Severine Vermeire, Anjali ...> ;Journal of Crohn's & Colitis. 2024 Feb 26
- Achievement of clinical, endoscopic, and histologic outcomes in patients with ulcerative colitis treated with etrasimod, and association with fecal calprotectin and C-...Panés, J., Jairath, V., Zhang, J., Rabbat, C., Sandborn, W., Vermeire, S., Peyrin-Biroulet, L., Yarur, A., Chiorean, M.> ;Journal of Crohn's & Colitis. 2024 Jan 20
- Join now to see all
Press Mentions
FDA Approves Zeposia for Moderate-to-Severe Ulcerative ColitisMay 28th, 2021- U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (Ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis1May 27th, 2021
- One Physician's Take on CME in the Era of COVID: ACG 2020November 9th, 2020
- Join now to see all
Professional Memberships
- Member
- Fellow
Hospital Affiliations
- Swedish Medical Center - Issaquah CampusIssaquah, Washington
MultiCare Yakima Memorial HospitalYakima, Washington
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
